

1 **Evaluation of a rapid lateral flow assay for the detection of taeniosis**
2 **and cysticercosis at district hospital level in Tanzania:**
3 **A prospective multicentre diagnostic accuracy study**

4
5 Inge Van Damme^{1,2¶}, Chiara Trevisan^{1,3¶}, Mwemezi Kabululu⁴, Dominik Stelzle⁵, Charles E.
6 Makasi^{6,7}, Veronika Schmidt-Urbaneja⁵, Kabemba E. Mwape⁸, Chishimba Mubanga⁹, Gideon
7 Zulu^{8,10}, Karen S. Møller¹¹, Famke Jansen¹², Dries Reynders¹³, John Noh¹⁴, Sukwan
8 Handali¹⁴, Emmanuel Bottieau¹⁵, Andrea S. Winkler^{5,16,17}, Pierre Dorny¹², Pascal
9 Magnussen¹⁸, Sarah Gabriël^{1&*}, Bernard Ngowi^{6,19&}

10

11 ¹ Department of Translational Physiology, Infectiology and Public Health, Faculty of
12 Veterinary Medicine, Ghent University, Merelbeke, Belgium

13 ² Service Foodborne Pathogens, Sciensano, Brussels, Belgium

14 ³ Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium;

15 ⁴ Tanzania Livestock Research Institute (TALIRI), Central Zone Office, Mpwapwa, Dodoma,
16 Tanzania

17 ⁵ Department of Neurology, Center for Global Health, Technical University of Munich,
18 Germany

19 ⁶ National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es
20 Salaam, Tanzania

21 ⁷ Kilimanjaro Christian Medical University College, Moshi, Tanzania

22 ⁸ Department of Clinical studies, School of Veterinary Medicine, University of Zambia,
23 Lusaka, Zambia

24 ⁹ Chishimba Mubanga: Ministry of Agriculture, Shibuyunji, Government of the Republic of
25 Zambia

26 ¹⁰ Gideon Zulu: Ministry of Health, Government of the Republic of Zambia.

27 ¹¹ Danish Food and Veterinary Administration, Denmark

28 ¹² Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

29 ¹³ Department of Applied Mathematics, Computer Science and Statistics, Ghent University

30 ¹⁴ Parasitic Diseases Branch, Division of Parasitic Diseases, Center for Global Health,
31 Centers for Disease Control and Prevention, USA

32 ¹⁵ Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

33 ¹⁶ Department of Community Medicine and Global Health, Institute of Health and Society,
34 University of Oslo, Norway

35 ¹⁷ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA,
36 USA

37 ¹⁸ Pascal Magnussen: Department of Immunology and Microbiology, Faculty of Health and
38 Medical Sciences, University of Copenhagen, Denmark

39 ¹⁹ University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya
40 Tanzania

41 * Corresponding author: sarah.gabriel@ugent.be

42 † These authors contributed equally to this work.

43 & These authors also contributed equally to this work

44

45 **Short title:** TS POC for taeniosis and cysticercosis

46 **Abstract**

47 The TS POC test, *Taenia solium* point-of-care test, is a two-strip lateral flow assay using the
48 recombinant antigen rES33 on the TS POC T test strip, and rT24H on the TS POC CC test
49 strip, to detect antibodies against *T. solium* taeniosis and cysticercosis, respectively.

50 The objective of this study was to assess the diagnostic performance of the TS POC test for
51 the detection of *T. solium* taeniosis and cysticercosis in individuals attending district hospitals
52 in Tanzania.

53 In this prospective two-phase diagnostic accuracy study, we recruited participants aged 10
54 and above, excluding pregnant women and those with acute severe illness. Participants were
55 consecutively recruited in three cohorts according to their signs/symptoms: compatible with
56 neurocysticercosis (cohort 1), intestinal worm infections (cohort 2), and other symptoms
57 (cohort 3). Lacking a gold standard test for both infections, evaluating the diagnostic
58 accuracy measures was done using the results of different coprological and serological tests
59 in a Bayesian Latent Class Model approach.

60 The TS POC test was conducted on 601 participants in cohort 1, 1661 participants in cohort
61 2, and 662 participants in cohort 3. Most individuals tested negative on both TS POC test
62 strips, with proportions of 83% (n = 496), 97% (n = 1613) and 97% (n = 641) in cohorts 1, 2
63 and 3, respectively. Sensitivity values for the TS POC T test strip were 50.2% [4.9 - 96.4],
64 40.8% [2.2 - 95.2], and 40.4% [2.3 - 95.0], while specificity values were 98.6% [97.1 - 99.6],
65 99.3% [98.7 - 99.7] and 99.4% [98.5 - 99.9], respectively. For the TS POC CC test strip, the
66 sensitivity was 77.5% [37.8 - 99.2], 24.9% [95% CI 6.4 - 52.7] and 44.2% [6.6 - 91.5], and
67 the specificity 92.3% [86.5 - 98.8], 99.1% [97.8 - 100], and 98.1% [96.1 - 99.7] across the
68 respective cohorts.

69 Although the TS POC test has a suboptimal sensitivity, it demonstrates a high specificity,
70 which may have clinical utility to guide treatment and diagnostic decisions, or in

71 epidemiological studies. An important strength of this study lies in its assessment of the TS
72 POC test under real-world conditions, revealing divergent estimates across distinct cohorts.
73 The study underscores the suboptimal performance of existing tests under field conditions,
74 emphasizing the need for the development and validation of better diagnostic tests.

75 **Keywords:** lateral flow assay; *Taenia solium*; resource-poor settings; rapid diagnostic test;
76 point of care

77 **Registration number:** PACTR201712002788898

78 **Author summary**

79 *Taenia solium* poses significant public health concerns globally and is a leading cause of
80 acquired epilepsy in *T. solium* endemic areas. The parasite causes two distinct infections in
81 humans: taeniosis, an intestinal infection, and cysticercosis, a tissue infection. The disease is
82 particularly prevalent in low-resource settings, contributing to substantial morbidity and
83 economic burdens. Recently, a test was specifically developed as an affordable and rapid
84 diagnostic tool, tailored for deployment in resource-constrained regions. The TS POC test is
85 composed of two test strips, one to detect taeniosis and one for cysticercosis. This study
86 provides a critical assessment of the diagnostic efficacy of the TS POC test in Tanzanian
87 district hospital settings. By evaluating the test's performance across diverse cohorts and real-
88 world conditions, the research sheds light on the limitations of existing diagnostic modalities
89 and underscores the imperative for improved testing strategies. The findings offer valuable
90 insights for public health practitioners and policymakers striving to enhance diagnostic
91 capabilities and ultimately mitigate the burden of *T. solium* infections in endemic regions.

92 **1 Introduction**

93 *Taenia solium* is an important zoonotic parasite, affecting humans and pigs. In humans,
94 infections can have different presentations. The adult tapeworm resides in the intestines of
95 humans (taeniosis), while its larvae can lead to a systemic infection (cysticercosis, CC).
96 Humans become infected with the tapeworm by consuming undercooked or raw pork that
97 contains cysticerci. When eggs of the tapeworm are ingested, larvae can encyst in various
98 tissues of the human body, including the central nervous system, causing neurocysticercosis
99 (NCC). The impact of *T. solium* on public health, economics, and social welfare is
100 significant, particularly in resource-limited settings. In Tanzania, the prevalence of *T. solium*
101 taeniosis and cysticercosis is high [1,2], resulting in significant public health and economic
102 consequences [3].
103 Diagnosis of *T. solium* taeniosis and cysticercosis in humans is currently performed through
104 laboratory-based methods targeting antigens and antibodies, such as enzyme-linked
105 immunosorbent assay (ELISA) and immunoelectrotransfer blot (EITB) assay [4,5], and also
106 basic coprological methods for taeniosis [6]. If there is a suspicion of NCC, either on clinical
107 grounds and/or positive cysticercosis serology, neuroimaging such as computed tomography
108 is the diagnostic tool of choice. Also, several molecular methods are available for the
109 diagnosis of taeniosis and the confirmation of cysticercosis lesions, which are mostly PCR-
110 based [4,7]. Most of these methods are time-consuming, expensive and/or not readily
111 available in rural areas, leading to a significant challenge in the management of these
112 infections [8]. Rapid diagnostic tests (RDTs) have revolutionized the field of diagnostics by
113 providing fast and easy-to-use tools for the detection of diseases in resource-limited settings.
114 However, the accuracy of RDTs is often questioned, as field validation is often not performed
115 [9].

116 For taeniosis, a rapid test that can be performed at the point of care (POC) would facilitate
117 timely and targeted treatment, reducing disease transmission. Furthermore, an easy and rapid
118 test for the detection of cysticercosis may be useful in patient care, disease monitoring
119 programs and epidemiological studies. As such, an easy-to-use POC test (called TS POC test)
120 has been developed for *T. solium* by the Centers for Disease Control and Prevention (CDC)
121 and the Technical University of Munich (TUM). The test showed a promising sensitivity and
122 specificity to detect *T. solium* taeniosis and NCC during its preliminary evaluation under
123 laboratory conditions. To evaluate its real-world performance in resource-poor, highly
124 endemic areas in sub-Saharan Africa, the performance characteristics of the TS POC test
125 were evaluated in two different settings: in rural communities in Zambia [10], and in district
126 hospitals in Tanzania [11]. The evaluation of the TS POC test for the detection of *T. solium*
127 taeniosis and cysticercosis at community level has been reported elsewhere [12,13]. Also the
128 evaluation of the TS POC test for the neuroimaging-based diagnosis of NCC in both settings
129 were reported elsewhere [14,15], and are thus out of the scope of this paper. The focus of this
130 paper is the evaluation of the TS POC test for the detection of infection with the adult
131 tapeworm (taeniosis) and/or the larval stage (cysticercosis) of *T. solium* in individuals
132 attending district hospitals (Tier 2 level) in Tanzania. The primary endpoints of this paper are
133 the sensitivity and specificity of the TS POC test for the detection of both infections,
134 evaluated in three different clinical cohorts.

135 **2 Material and methods**

136 The trial was registered at the Pan African Clinical Trials Registry with identifier
137 PACTR201712002788898. A comprehensive description of the trial rationale, design and
138 methodology can be found in Trevisan et al. [11]. Only the methodological details relevant
139 for this manuscript are summarized in this paper, i.e. only focusing on *T. solium* taeniosis and

140 cysticercosis testing. The evaluation of the TS POC CC test strip for NCC diagnosis is
141 described elsewhere [14,15].

142 **2.1 Study design**

143 The study was designed as a prospective, two-phase, multicentre diagnostic accuracy study.
144 First, all participants were tested using the TS POC test (phase 1), after which all participants
145 testing positive and a subset of the participants testing negative were requested to provide a
146 blood and stool sample for further reference testing (phase 2). Since there is no gold standard
147 as comparison method for neither of the infections, the performance of the TS POC test was
148 assessed using a combination of reference tests. The details of these tests can be found in
149 section 2.4, sample collection and reference testing. The TS POC test is a two-strip lateral
150 flow assay prototype. The primary aim of this paper is to determine the sensitivity and
151 specificity of the TS POC T test strip and TS POC CC test strip for the detection of *T. solium*
152 taeniosis and cysticercosis, respectively, in individuals attending district hospitals in
153 Tanzania. As sensitivity and specificity are known to differ between study populations, the
154 evaluation was done in three different cohorts: 1) individuals with specific neurological signs
155 and symptoms compatible with NCC (epilepsy and/or severe progressive headache) (from
156 now on referred to as « cohort 1 »); 2) individuals with complaints compatible with intestinal
157 worm infections such as abdominal pain and loss of appetite (cohort 2); and 3) individuals
158 with other symptom(s), such as coughing, limb pain, hypertension, and diabetes patients
159 (cohort 3).

160 **2.2 Participants**

161 Participants were enrolled between December 2017 and February 2020 in three district
162 hospitals in southern Tanzania: Mbeya (rural) District (Ifisi) and Rungwe District (Tukuyu),
163 both located in Mbeya Region, and Mbozi District (Vwawa), located in Songwe Region. To

164 be included, individuals aged 10 years or above had to be willing and able to provide written
165 informed consent, living in the study area for the past three months and planning to stay in
166 the same area throughout the study period. Pregnant women and individuals with acute severe
167 illness that needed in-patient care were excluded. Different additional criteria were used to be
168 included in the different cohorts.

169 Individuals with signs/symptoms compatible with NCC (cohort 1) were consecutively
170 recruited from Outpatient Departments (OPD) and the Mental Health Clinics (MHC). A
171 questionnaire consisting of nine questions was used to assess if individuals fulfilled the
172 criteria for epileptic seizures and/or severe progressive headache (S1 Appendix; more details
173 can be found in Stelzle et al. [14,16]). For cohort 2, individuals who presented at the OPD
174 with complaints compatible with intestinal worm infection were included. They needed to
175 have at least one of the following signs/symptoms: abdominal pain/discomfort, having seen
176 worm parts in the stool, express having a worm in the stomach, nausea, diarrhoea and loss of
177 appetite. All other people presenting at the OPD, without signs/symptoms compatible with
178 cohort 1 or cohort 2, were potential candidates to be included in cohort 3. Participants with
179 epilepsy and/or headache (cohort 1) or symptoms compatible with intestinal worm infections
180 (cohort 2) were consecutively recruited. For cohort 3, every 10th individual was approached
181 for enrolment in the study.

182 Eligible participants were informed about the study and were invited to provide informed
183 consent. Written informed consent (assent for minors, with written consent of
184 parent/guardian) was obtained from all participants. Following consent, demographic and
185 clinical data were collected from participants, including self-reported age, and gender.

186 **2.3 TS POC test**

187 The TS POC is an antibody-detecting lateral flow assay, using two test strips, each with a
188 previously characterised recombinant protein, rES33 for the TS POC T test strip and rT24H
189 for the TS POC CC test strip [17,18]. During initial assessments conducted within laboratory
190 settings using known positive and negative control sera, the TS POC test demonstrated
191 encouraging results. The TS POC T test strip exhibited a sensitivity of 82% and a specificity
192 of 99% in detecting taeniosis. In the case of NCC, the TS POC CC test strip had a sensitivity
193 of 88%, and 93% for infection with multiple cysticerci, with a corresponding specificity of
194 99%. The TS POC cassette prototype was assembled at CDC, Atlanta.

195 Details about the TS POC test and testing procedures have been described elsewhere
196 [10,12,13,19]. In short, 20 μ L blood was collected from a fingertip and placed in a sample
197 port of one of the test strips, and the same procedure was repeated for the other test strip.
198 After applying chase buffer, the TS POC test was read after 20 minutes. A TS POC test strip
199 was considered positive when the control line and test line were positive (visible as a red
200 line). The result was invalid when the control line was negative. The result was negative
201 when the control line was positive and test line negative. The results were read by two
202 different readers. When there was disagreement between the readers, the result of a third
203 reader was decisive.

204 **2.4 Sample collection and reference testing**

205 Participants testing positive for one or both TS POC test strips, and every 10th participant
206 testing negative on both strips, were further sampled and tested. Since there is no gold
207 standard test available for taeniosis nor cysticercosis, multiple imperfect tests were used as
208 reference tests. For taeniosis, the following three tests were used: 1) copro Ag ELISA
209 according to Allan et al. [20] and modified by Mwape et al. [21] to detect *Taenia* antigens in
210 stool using a predefined cut-off value; 2) copro mPCR according to Yamasaki et al. [7] to

211 detect *Taenia* DNA in stool, which was considered positive only when a 720 bp *T. solium*
212 band was visible; and 3) rES33-EITB to detect antibodies in serum [22], which was positive
213 when the rES33 band was visible. For cysticercosis, two serum-based tests were used: 1)
214 serum Ag ELISA to detect antigens [23] using a pre-determined protocol to determine the
215 cut-off value, and 2) rT24H-EITB to detect antibodies [17], which was considered positive
216 when the rT24H band was visible. Although also the LLGP-EITB was initially planned to be
217 included in the study [11], the results of this in-house test could not be used due to doubts
218 about the validity of the test results [13]. Further details regarding the reference tests are
219 available in the study protocols [10,11]. No adverse events were recorded.

220 Samples were shipped from Tanzania to Belgium for analysis. The PCR assays, copro Ag
221 ELISA and immunoblots were performed at the Institute of Tropical Medicine (Antwerp,
222 Belgium). Serum Ag ELISA was performed at Ghent University (Merelbeke, Belgium).

223 Samples arriving at the laboratories were only labelled with a pseudonymized code, so
224 laboratory personnel performing the tests were blinded to the TS POC result and the
225 participant's cohort.

226 **2.5 Statistical analysis**

227 **2.5.1 Bayesian analysis**

228 The primary objective of this paper was to determine the sensitivity and specificity of: 1) the
229 TS POC T test strip for the detection of taeniosis, and 2) the TS POC CC test strip for the
230 detection of cysticercosis. Due to the lack of a gold standard test for infection with adult
231 worm and larval stages of *T. solium*, diagnostic accuracy measures were estimated using a
232 Bayesian Latent Class Model (BLCM)-like approach according to Berkvens et al. [24] using
233 Open BUGS software version 3.2.3 (www.openbugs.net). The analysis allowed the

234 sensitivities and specificities to differ conditional on the other test results. The analyses were
235 performed for each of the three cohorts separately.

236 This study was reported following the Standards for Reporting of Diagnostic Accuracy
237 studies that use BLCMs (STARD-BLCM) [25].

238 Sensitivity and specificity of the TS POC test were considered co-primary endpoints. The
239 positive/negative predictive values, the prevalence, and the accuracy measures of the
240 reference tests were also estimated using the models and were considered exploratory
241 endpoints.

242 *2.5.1.1 Handling missing and inconclusive results*

243 The test strips of the TS POC test were read by two readers, and a third reader in case the first
244 two readers disagreed. There were no inconclusive TS POC results found. For cysticercosis,
245 participants with one or more missing blood results were excluded from the analysis, and for
246 taeniosis, participants with a missing result for a blood test and/or stool test were excluded,
247 i.e. a complete case analysis was performed. To avoid partial verification bias due to the two-
248 phase sampling, the multinomial probabilities in the models were adapted according to the
249 observed sampling frequencies. The weighting was determined by the proportion of complete
250 cases per test strip result.

251 *2.5.1.2 Priors*

252 For the probabilistic constraints in the Bayesian analyses, initially the same priors were used
253 as described previously, for the evaluation of the TS POC test accuracy at community level
254 (Mubanga, Trevisan, et al., 2021; Mubanga, Van Damme, et al., 2021). However, the priors
255 were revised since diagnostic accuracy measures differ according to the target population,
256 and the data did not support the priors in certain models, as demonstrated by high Bayesian P
257 values (see S2 Appendix for all model outcomes). Therefore, new priors were defined based

258 on the knowledge that was obtained about the test performance during the field studies at
259 community level (Mubanga, Trevisan, et al., 2021; Mubanga, Van Damme, et al., 2021). The
260 outputs of the least restrictive models of the community-based studies were used as a basis to
261 determine the new sets of priors and were updated after a more thorough literature search
262 whenever necessary. The priors that were used during the first (initial priors) and second
263 (new priors) round of analyses, including the rationale, are given in S2 Appendix.

264 2.5.1.3 *Models*

265 Only the output of the final models is reported in the main article for clarity, but the output of
266 all models that were performed can be found in S2 Appendix for completeness. The output of
267 the new sets of priors was used as the final model for most analyses. Only for the evaluation
268 of cysticercosis tests in cohort 2, the results from the model using the least restrictive original
269 priors were used because this model fitted considerably better compared to the model using
270 the new priors (Bayesian p value of 0.635 and 0.790, respectively; see S2 Appendix).

271 Due to the low number of positive cases for taeniosis, all analyses for taeniosis were repeated
272 for the three cohorts combined. When combining the three cohorts, one overall prevalence
273 (for the mixture of the three cohorts) was estimated, and the conditional sensitivities and
274 specificities were assumed to be equal. The overall models (combining the three cohorts) are
275 included in S2 Appendix, but they are not reported in the main manuscript due to the high
276 Bayesian p values, indicating a bad fit.

277 For the evaluation of the TS POC T strip, the TS POC CC test strip result was included in all
278 models to account for the relatively large number of TS POC CC positive participants within
279 TS POC T negative complete cases. Since rES33-EITB detects exposure (antibodies) whereas
280 copro mPCR and copro Ag ELISA detect infection (parasitic DNA and proteins,
281 respectively), the analyses were also repeated without rES33-EITB to estimate the accuracy
282 for detecting active infection. The estimates from models with and without rES33-EITB were

283 very similar (see S2 Appendix), so only the models including rES33-EITB are reported as
284 final model for taeniosis.

285 **2.5.2 Agreement between tests**

286 Cohen's kappa statistics, and positive/negative agreements were calculated to explore the
287 agreement between different tests [26]. The observed frequencies of the complete cases were
288 inversely weighted according to their sampling frequencies to calculate the measures of
289 agreement.

290 **2.5.3 Sample size and descriptive statistics**

291 The sample sizes were calculated to obtain a desired precision of 10% around the sensitivity
292 and specificity of the TS POC test, resulting in 600 individuals in cohort 1, and 2000
293 individuals, distributed over cohort 2 and 3 [11]. Demographic characteristics of participants
294 were reported descriptively, using R version 4.2.3 [27].

295 **2.6 Ethical clearance**

296 The study adhered to the principles outlined in the Declaration of Helsinki and obtained
297 ethical approval from the National Ethics Health Research Committee (NatREC) of Tanzania
298 (NIMR/HQ/R.8a/Vol.IX/2597), the Institute of Tropical Medicine (IRB/AB/ac/112 Ref
299 1177/17) through the ethics committee of the University of Antwerp (EC UZA 17/31/352),
300 and the Technical University of Munich via their Ethics Committee at the Klinikum rechts
301 der Isar, Munich (299/18S).

302 **3 Results**


303 **3.1 Study population**

304 In total, 3055 participants were recruited in three district hospitals in Tanzania. Participants
 305 were recruited for neurological signs/symptoms compatible with NCC (cohort 1, n = 742);
 306 complaints compatible with intestinal worm infection (cohort 2; n = 1661); and other
 307 symptoms (cohort 3; n = 663). The flows for each of the three cohorts are visualised in Figs
 308 1-3, respectively. The TS POC test was performed in 601 participants of cohort 1, 1661
 309 participants of cohort 2, and 662 participants of cohort 3. The baseline characteristics of these
 310 participants in each of the three cohorts are given in Table 1. The median age varied between
 311 33 and 40 years and the proportion of women varied between 52% and 69%.

312 **Table 1. Baseline characteristics of participants tested using the TS POC test, in each of the three**
 313 **cohorts, recruited in three district hospitals in Tanzania.**

	Cohort 1 (n = 601)	Cohort 2 (n = 1661)	Cohort 3 (n = 662)
Age (in years)			
Mean	36	38	43
Median [interquartile range]	33 [23]	33 [32]	40 [28]
Gender			
Female (%)	313 (52%)	1146 (69%)	445 (67%)
Male (%)	288 (48%)	515 (31%)	217 (33%)


314 Cohort 1: people with specific neurological signs and symptoms (epilepsy and/or severe progressive
 315 headache); cohort 2: people with complaints compatible with intestinal worm infections; cohort 3: people
 316 with any other symptom(s).
 317



318

319 **Figure 1. Flow diagram of participants with specific neurological signs and symptoms compatible**
 320 **with NCC (cohort 1).**


321 TS POC: *T. solium* point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked
 322 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia*
 323 antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro
 324 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent
 325 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test
 326 results refer to the number of positive samples.



327

328 **Figure 2. Flow diagram of participants with complaints compatible with intestinal worm**
 329 **infections (cohort 2).**

330 TS POC: *T. solium* point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked
 331 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia*
 332 antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro
 333 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent
 334 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test
 335 results refer to the number of positive samples.



336

337 **Figure 3. Flow diagram of participants attending district hospitals with symptoms other than**
 338 **neurological and gastro-intestinal (cohort 3).**

339 TS POC: *T. solium* point-of-care test; rT24H-EITB: recombinant T24H enzyme-linked
 340 immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting *Taenia*
 341 antigens in serum; rES33-EITB: recombinant ES33 enzyme-linked immunoelectrotransfer blot, copro
 342 mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA: enzyme-linked immunosorbent
 343 assay detecting *Taenia* antigens in stool. The numbers after each of the taeniosis and cysticercosis test
 344 results refer to the number of positive samples.

345

346 In cohort 1, 422 participants were recruited from the mental health clinic, and 170 from the
 347 outpatient department (S1 Appendix). Based on the initial screening questionnaire
 348 administered by local nurses, participants were recruited for both headache and epilepsy (n =
 349 307), only epilepsy (n = 169) or only headache (n = 125). An overview of symptoms based
 350 on the screening questionnaires is given in S1 Appendix. More details regarding the

351 characteristics and neurological signs/symptoms of participants in cohort 1 can be found in
352 Stelzle *et al.* [16].
353 In cohort 2, participants were included with gastro-intestinal symptoms. Out of the
354 participants with complete data for the screening questionnaire (n = 1537), most indicated to
355 have three (n = 595) or two (n = 568) symptoms, and fewer had one (n = 252), four (n = 117)
356 or five (n = 5) symptoms. Most participants reported abdominal pain/discomfort (n = 1438),
357 followed by loss of appetite (n = 827), nausea (n = 796), diarrhoea (n = 403), express having
358 a worm in the stomach (n = 110) and having seen worm parts in their stool (n = 92).

359 **3.2 TS POC test results**

360 Within the three cohorts, most participants tested negative using both TS POC test strips (n =
361 496, 83%; n=1613, 97%; n=641, 97% in cohort 1, 2 and 3, respectively). All participants who
362 were positive for at least one test strip and a subset of participants negative using both test
363 strips were selected to give a blood and stool sample for reference testing. Overall, 287
364 complete cases, *i.e.* results available for all reference tests, were obtained for the evaluation
365 of taeniosis, and 303 complete cases were obtained for cysticercosis. Details regarding the TS
366 POC result combinations within each of the cohorts can be found in the respective flow
367 diagrams (Figs 1-3).

368 **3.3 Taeniosis tests**

369 Most participants provided a stool sample immediately after recruitment, with a median
370 duration of two days between the TS POC test and processing of the stool sample in the
371 hospital lab (based on 220 participants for whom both dates were known). Nevertheless, 27
372 participants provided a stool sample more than one month after recruitment.

373 **3.3.1 Reference test results**

374 Table 2 shows the results of the 287 complete cases for the evaluation of *T. solium* taeniosis,
 375 per cohort. Within TS POC T negative participants, the majority (231/267, 87%) tested
 376 negative using all taeniosis reference tests. Also, within TS POC T positive complete cases,
 377 most participants (12/20, 60%) tested negative using all reference tests.

378 **Table 2. Cross tabulation of the tests used to detect taeniosis within the three cohorts (complete**
 379 **cases only, n = 287).**


TS POC T test strip	rES33-EITB	Copro mPCR	Copro Ag ELISA	Cohort 1		Cohort 2		Cohort 3		Total
				TS POC CC-	TS POC CC+	TS POC CC-	TS POC CC+	TS POC CC-	TS POC CC+	
negative	negative	negative	negative	27	63	73	22	34	12	231
negative	negative	negative	positive	0	4	3	0	1	2	10
negative	negative	positive	positive	0	1	1	0	0	0	2
negative	positive	negative	negative	0	16	3	4	0	1	24
positive	negative	negative	negative	2	1	5	1	2	1	12
positive	negative	negative	positive	0	1	0	0	0	0	1
positive	positive	negative	negative	1	3	0	2	0	0	6
positive	positive	positive	positive	0	1	0	0	0	0	1

380 TS POC T: *T. solium* point-of-care test strip for taeniosis; rES33-EITB: recombinant ES33 enzyme-linked
 381 immunoelectrotransfer blot, copro mPCR: multiplex polymerase chain reaction in stool, copro Ag ELISA:
 382 enzyme-linked immunosorbent assay detecting *Taenia* antigens in stool. The numbers within each cohort
 383 represent the number of participants for each TS POC T and TS POC CC test strip result combination. A
 384 two-phase design was used, selecting only a subset of the TS POC negative population for reference
 385 testing, so particularly participants that were negative using both TS POC test strips are
 386 underrepresented. Combinations of test results that did not occur in the dataset are not included in the
 387 table.

388 3.3.2 Diagnostic performance measures

389 The TS POC T test strip had an estimated sensitivity of 50.2% [95% CI 4.9 - 96.4] in cohort
 390 1, 40.8% [2.2 - 95.2] in cohort 2, and 40.4% [2.3 - 95] in cohort 3. The specificity was 98.6%
 391 [97.1 - 99.6], 99.3% [98.7 - 99.7] and 99.4% [98.5 - 99.9], respectively. The sensitivity and

392 specificity of the TS POC T test strip, rES33-EITB, copro Ag ELISA and copro mPCR are
393 visualised in Figure 4. The estimated sensitivities of all tests were low, ranging from 40.8%
394 to 56.5%, and all had wide credible intervals. The prevalence of *T. solium* taeniosis in the
395 cohorts was estimated at 1.1% [0.1 - 3.5] (cohort 1), 0.3% [0 - 1.4] (cohort 2), and 0.5% [0 -
396 2.4] (cohort 3). The positive predictive values of the TS POC T test strip were 25% [0.9 -
397 71.6], 10% [0.2 - 41.2], and 20.1% [0.4 - 73.1], and the negative predictive values were
398 99.4% [97.2 - 100], 99.8% [98.8 - 100], 99.6% [97.9 - 100], and 99.8% [98.9 - 100] for the
399 three cohorts, respectively (S2 Appendix).



400

401 **Figure 4. Sensitivity and specificity of the TS POC T test strip, rES33-EITB, copro Ag ELISA and**
 402 **copro mPCR to detect taeniosis in three cohorts of participants recruited at district hospitals in**
 403 **Tanzania.**

404 Results of the same cohort are indicated with the same colour. The error bars indicate the 95% credible
 405 intervals around the mean estimates. Cohort 1: participants with specific neurological signs and
 406 symptoms compatible with NCC (epilepsy and/or severe progressive headache); cohort 2: participants
 407 with complaints compatible with intestinal worm infections; cohort 3: participants with other
 408 symptom(s). TS POC T: *T. solium* point-of-care test strip for taeniosis; rES33-EITB: recombinant ES33
 409 enzyme-linked immunoelectrotransfer blot, copro Ag ELISA: enzyme-linked immunosorbent assay
 410 detecting *Taenia* antigens in stool, copro mPCR: multiplex polymerase chain reaction in stool.

411 3.3.3 Agreement between taeniosis tests

412 The point estimates for agreement and positive agreement were low among all tests for
 413 taeniosis (Table 3). Due to the low number of test positive samples, the estimates for
 414 agreement should be interpreted with caution. There was no agreement between the TS POC
 415 T test and any of the reference tests within cohort 2 and cohort 3. Also, the agreement
 416 between rES33-EITB and the stool-based tests was low, with positive agreements from 0 to

417 8%. Only within cohort 1, the agreement between the TS POC T test strip and rES33-EITB
 418 was fair, with 31% positive agreement. All three copro mPCR positive cases within this
 419 cohort were also positive using copro Ag ELISA.

420 **Table 3. Agreement between the different tests for taeniosis and cysticercosis, for the three**
 421 **different cohorts of participants.**

	<i>Cohort 1</i>	<i>Cohort 2</i>	<i>Cohort 3</i>
<i>Taeniosis tests</i>			
<i>TS POC T - rES33-EITB</i>	0.29 0.31 0.98	0.04 0.05 0.98	0.00 0.00 1.00
<i>TS POC T - copro mPCR</i>	0.17 0.18 0.99	-0.01 0.00 0.99	0.00 0.00 1.00
<i>TS POC T - copro Ag ELISA</i>	0.23 0.24 0.99	-0.01 0.00 0.97	-0.01 0.00 0.98
<i>rES33-EITB - copro mPCR</i>	0.07 0.08 0.98	-0.02 0.00 0.97	0.00 0.00 1.00
<i>rES33-EITB - copro Ag ELISA</i>	0.05 0.06 0.98	-0.04 0.00 0.95	0.00 0.00 0.98
<i>Copro mPCR - copro Ag ELISA</i>	0.43 0.43 1.00	0.39 0.40 0.98	0.00 0.00 0.98
<i>Cysticercosis tests</i>			
<i>TS POC CC - rT24H-EITB</i>	0.66 0.70 0.95	0.33 0.35 0.98	0.38 0.39 0.99
<i>TS POC CC - serum Ag ELISA</i>	0.57 0.63 0.94	0.27 0.30 0.97	0.15 0.18 0.95
<i>rT24H-EITB - serum Ag ELISA</i>	0.74 0.76 0.97	0.18 0.22 0.96	0.10 0.11 0.96

422 The numbers indicate Cohen's kappa, positive and negative agreement, respectively. Point estimates were
 423 calculated based on complete cases, which were inversely weighted according to their observed sampling
 424 frequencies (according to the TS POC C and TS POC T result combination) to account for the study design.

425 **3.4 Cysticercosis**

426 **3.4.1 Reference test results**

427 The results of cysticercosis tests for the complete cases within each of the three cohorts is
 428 shown in Table 4. Within TS POC CC negative complete cases, only few were positive using
 429 either serum Ag ELISA or rT24H-EITB, and none of the POC CC negative participants
 430 tested positive using both reference tests simultaneously. Within TS POC CC positive

431 complete cases, most participants tested positive using both reference tests or negative using
 432 both reference tests (Table 4).

433 **Table 4. Cross tabulation of the tests used to detect cysticercosis within the three cohorts of**
 434 **participants (complete cases only; n = 303).**


TS POC CC test strip	rT24H- EITB	Serum Ag ELISA	Cohort 1		Cohort 2		Cohort 3		Total
			POC T-	POC T+	POC T-	POC T+	POC T-	POC T+	
negative	negative	negative	29	3	80	5	34	2	153
negative	negative	positive	1	0	4	0	3	0	8
negative	positive	negative	0	0	3	0	0	0	3
positive	negative	negative	36	1	13	1	9	0	60
positive	negative	positive	6	0	1	0	3	0	10
positive	positive	negative	6	0	1	0	0	1	8
positive	positive	positive	39	5	12	2	3	0	61

435 TS POC CC: *T. solium* point-of-care test strip for cysticercosis; rT24H-EITB: recombinant T24H enzyme-
 436 linked immunoelectrotransfer blot, serum Ag ELISA: enzyme-linked immunosorbent assay detecting
 437 *Taenia* antigens in serum. The numbers within each cohort represent the number of participants for each
 438 result combination. A two-phase design was used, selecting only a subset of the TS POC negative
 439 population for reference testing, so participants that were negative on both TS POC test strips are
 440 underrepresented.

441 3.4.2 Diagnostic performance of cysticercosis tests

442 The complete cases in Table 4 were used to estimate the performance characteristics of the
 443 TS POC CC test strip, for each of the three cohorts separately. The sensitivity and specificity
 444 of the final models are visualised in Figure 5. The sensitivity of the TS POC CC test strip was
 445 77.5% [37.8 - 99.2] in cohort 1, 24.9% [6.4 - 52.7] in cohort 2, and 44.2% [2.3 - 95] in cohort
 446 3. The specificity was 92.3% [86.5 - 98.8], 99.1% [97.8 - 100], and 98.1% [96.1 - 99.7],
 447 respectively. The point estimates of the sensitivity of all tests were higher in cohort 1 than in
 448 the other two cohorts. The prevalence of cysticercosis was estimated at 15.3% [8.1 - 29.4]
 449 (cohort 1), 9.4% [5.1 - 23.9] (cohort 2), and 5.1% [0.8 - 17.1] (cohort 3). Positive predictive

450 values of the TS POC CC test strip were 63.3% [44.1 - 94.5], 71.6% [35.4 - 98.8], and 46.6%
451 [13.5 - 91.2], and negative predictive values 95.1 [79.4 - 99.9], 92.4% [77.4 - 97.3], and
452 96.4% [84.2 - 99.9], respectively (S2 Appendix).



453
454 **Figure 5. Sensitivity and specificity of the TS POC CC test strip, rT24H-EITB and serum Ag ELISA to**
455 **detect cysticercosis in three cohorts recruited in three district hospitals in Tanzania.**

456 Results of the same cohort are indicated with the same color. The error bars indicate the 95% credible
457 intervals around the mean estimates. Cohort 1: participants with specific neurological signs and
458 symptoms compatible with NCC (epilepsy and/or severe progressive chronic headache); cohort 2:
459 participants with complaints compatible with intestinal worm infections; cohort 3: participants with
460 other symptom(s). TS POC CC: *T. solium* point-of-care test for cysticercosis; rT24H-EITB: recombinant
461 enzyme-linked immunoelectrotransfer blot; serum Ag ELISA: serum antigen enzyme-linked
462 immunosorbent assay.

463 3.4.3 Agreement between cysticercosis tests

464 Cohen's kappa, positive and negative agreements between each of the different tests are
465 shown in Table 3, for each of the three cohorts. The agreement between the TS POC CC
466 result and the rT24H-EITB was substantial within cohort 1 ($\kappa = 66\%$), but only fair within

467 the other cohorts ($\kappa = 33\text{-}38\%$). Within each cohort, the agreement of TS POC CC with
468 serum Ag ELISA was lower than the agreement with rT24H-EITB (Table 3). In cohort 1,
469 there was a substantial agreement between the rT24H-EITB and serum Ag ELISA ($\kappa = 74\%$),
470 whereas the agreement between both tests in the other cohorts was low ($\kappa < 20\%$). The
471 negative agreements were all above 94%, but the positive agreements were lower, varying
472 between 11% and 76%.

473 **4 Discussion**

474 The primary objective of this study was to assess the sensitivity and specificity of the TS
475 POC test under field conditions in people attending district hospitals in Tanzania for the
476 detection of taeniosis and cysticercosis. The study lateral-flow test demonstrated a moderate
477 sensitivity for cysticercosis detection in individuals suspect of (neuro)cysticercosis. In
478 contrast, the sensitivity was largely unsatisfactory for the detection of taeniosis even in
479 clinical suspects. The relatively high specificity of the test may be useful in clinical care.
480 We used several strategies to minimize bias in this diagnostic accuracy study [10,11]. Despite
481 these efforts, certain factors may have affected the sensitivity and specificity estimates. One
482 potential source of bias for the taeniosis evaluation is the time interval between the initial test
483 and the stool sample collection, which could result in disease progression bias. Although
484 most participants submitted a stool sample within two days of the TS POC test, some waited
485 considerably longer to return a stool sample, raising the possibility of infection acquisition or
486 changes in egg excretion during the interval. In contrast, blood samples were collected
487 promptly by a nurse, thus limiting the risk of disease progression bias. Logistical issues, such
488 as sample shipment and COVID-19-related delays, may have further affected test outcomes.
489 Prolonged storage could have led to false negatives and variations in the stability of
490 antibodies, antigens, and DNA, could have contributed to the observed low agreement

491 between tests. Our two-stage design, sampling all POC test positives and a subset of
492 negatives, aimed to reduce the number of reference tests. However, due to the lower
493 sensitivity of the TS POC test than the preliminary laboratory tests, we only identified few
494 infections, particularly for taeniosis, which resulted in wide credible intervals for sensitivity.
495 Despite these limitations, this study showed valuable insights in diagnostic tests for *T. solium*
496 infections in hospital settings. Its main strength was evaluating the test in target populations,
497 yielding more realistic estimates than diagnostic case-control studies conducted in laboratory
498 settings.

499 Rapid diagnostic tests can be particularly useful for identifying *T. solium* taeniosis, as they
500 shorten diagnostic turnaround times and enable quicker treatment, preventing the spread of
501 infectious eggs. A high sensitivity is essential to avoid missing infected individuals. In our
502 study, the TS POC T test strip had a sensitivity of 40% to 50%, with wide credible intervals,
503 falling short of the 95% sensitivity threshold recommended in Target Product Profiles (TPPs)
504 for monitoring of control interventions, as well as for diagnosis and treatment [8].

505 Additionally, rES33-EITB, copro Ag ELISA and copro mPCR also showed sensitivities
506 below the 95% TPP threshold, highlighting the need for improved diagnostic methods
507 validated under field conditions. The low disease prevalence complicates sensitivity
508 assessment, as seen in our cohorts where true prevalence was very low and similar to 0.6%
509 [28] and 1.8% [12] in rural communities of Eastern Province of Zambia. Achieving a
510 sensitivity above the 95% TPP threshold for taeniosis tests under field conditions with current
511 tests and low prevalence would thus require very large studies to achieve accurate field
512 validation.

513 The sensitivity of the TS POC CC test strip for detecting infection with cysticerci varied
514 across the different cohorts. These differences were expected due to varying disease spectra
515 among populations. Sensitivity was low among participants with gastrointestinal symptoms

516 (25% [6 – 53%]) and other symptoms (44% [2 – 95%]), similar to rates observed in
517 asymptomatic rural communities in Zambia (35% [14–63%]) [13]. The sensitivity was higher
518 among participants with neurological signs/symptoms (77% [38-99%]), likely due to higher
519 parasitic loads, resulting in elevated antibody/antigen levels [29], which are more easily
520 detected by a diagnostic test. As such, both rT24H-EITB and serum Ag ELISA also
521 demonstrated higher sensitivities in individuals with neurological signs/symptoms compared
522 to the other cohorts and asymptomatic community members [13]. Consequently, also the
523 agreement between the different cysticercosis tests was higher in individuals with
524 neurological signs/symptoms than in the other cohorts and asymptomatic community
525 members [13]. The almost perfect agreement that has been reported for different NCC tests
526 [30–32] should thus be interpreted cautiously, as it may not be representative for the target
527 population. Differences in test agreement among subgroups stratified by location and stage of
528 the lesions [33] further suggests variability according to disease spectrum. Similarly, the TS
529 POC CC test strip and serological tests showed a sensitivity of 44 to 50% for NCC diagnosis
530 in hospital settings, but above 98% among patients with active lesions [14]. This study shows
531 that agreement between serological tests is only minimal to moderate under field conditions,
532 particularly in individuals not clinically suspect of NCC.

533 There is no gold standard test for diagnosing cysticercosis, and existing tests have been
534 evaluated almost exclusively for neuroimaging-based detection of NCC [29–34], often in
535 (severely diseased) symptomatic patients in diagnostic case-control studies. This leads to an
536 overestimation of the diagnostic performance in laboratory settings [35], making these
537 estimates not representative for the target population. The lack of data on test performance
538 for cysticercosis detection made selecting prior information challenging. Priors were updated
539 based on community-level evaluation data [13], and were chosen to be minimally restrictive,

540 contributing to wide credible intervals. More knowledge on serological test performance
541 under field conditions is urgently needed, not just for NCC.
542 Compared to the sensitivities, the specificities of all tests were more precisely estimated and
543 generally high, exceeding 90% in all cohorts. When used in a magnetic
544 immunochromatographic test, the rES33 antigen had a specificity of 96% using serum from
545 regions without taeniosis/cysticercosis transmission, with some reactivity in patients infected
546 with *Echinococcus granulosus*, *Ascaris lumbricoides*, *Plasmodium falciparum*, *Trichinella*
547 and *Schistosoma mansoni* [36]. As we evaluated the tests in an endemic region and under
548 field conditions, the specificity estimates that were obtained in our study are likely more
549 realistic than the ones obtained using diagnostic case-control studies. Despite the potential
550 presence of comorbid infections in our study populations, the specificity of the TS POC test
551 seems rather high, and may be useful for epidemiological studies and monitoring of
552 interventions. Nevertheless, when the disease prevalence decreases, a very high specificity is
553 required [37], so the specificity of the tests would have to be evaluated in post-intervention
554 populations to determine if it is fit for purpose.

555 **5 Conclusions**

556 The TS POC test demonstrated a moderate sensitivity for infections with cysticerci in
557 individuals with neurological signs/symptoms, but a high specificity, which could be useful
558 for the care of this population. In contrast, the sensitivity was largely unsatisfactory for the
559 detection of *T. solium* taeniosis, even in clinical suspected cases, an infection for which
560 straightforward treatment is available. This study also highlights the lack of knowledge on the
561 performance of the currently used diagnostic tests for *T. solium* taeniosis and cysticercosis
562 under field conditions. Most tests have only been evaluated in laboratory settings using
563 diagnostic case-control studies, resulting in an overestimation of the diagnostic performance

564 of the tests. Additionally, transforming a continuous variable, such as antibody levels or DNA
565 concentrations, into a binary outcome (presence or absence of infection) leads to a loss of
566 valuable information, which can result in misclassification and diminish the overall accuracy
567 of a diagnostic test. The variability in test performance across different cohorts underscores
568 the importance of estimating the diagnostic accuracy of a test in the intended target
569 population, and that the sensitivity cannot be extrapolated to populations with a different
570 disease spectrum. Since also the reference tests in the current study performed poorly under
571 field conditions, this study showed the overall need to develop more sensitive and specific
572 diagnostic tests to detect human *T. solium* taeniosis and cysticercosis.

573 **6 Acknowledgements**

574 We extend our gratitude to all the dedicated hospital staff members and the willing
575 participants for their invaluable contributions to this study. Special recognition is also due to
576 the laboratory technicians, Sandra Vangeenberghe, Maxwell Masuku, Chembensofu
577 Mwelwa, Anke Van Hul, Ana Lucia Fajardo for their diligent analysis of the samples.
578 Special thanks are due to the members of the SOLID External Advisory Board for their
579 guidance, and Helena Ngowi and Maria V. Johansen for their valuable contributions during
580 the initial phase of this study. This work is dedicated to the memory of our esteemed
581 colleague and friend, Dr. Benedict Ndawi.

582 **7 Data availability**

583 The data cannot be publicly shared due to ethical and privacy considerations but are
584 accessible through the Data Access Committee at the Institute of Tropical Medicine,
585 Antwerp. You can find more information and request access via [https://www.itg.be/E/data-](https://www.itg.be/E/data-sharing-open-access)
586 [sharing-open-access](https://www.itg.be/E/data-sharing-open-access), or via email at ITMresearchdataaccess@itg.be.

587 **8 Funding**

588 Funding for this research was provided by the European & Developing Countries Clinical
589 Trials Partnership (grant number DRIA2014-308) and the German Federal Ministry of
590 Education and Research (grant number 01KA1617) as part of the research grant titled
591 "Evaluation of an antibody detecting point-of-care test for the diagnosis of *Taenia solium*
592 taeniosis and (neuro)cysticercosis in communities and primary care settings of highly
593 endemic, resource-poor areas in Tanzania and Zambia, including training of and technology
594 transfer to the Regional Reference Laboratory and health centers (SOLID)". The funders of
595 this research had no role in this study.

596 **9 Declaration of interest**

597 VS, JN and SH were involved in the development of the TS POC test. ITM (Nationalestraat
598 155, B-2000 Antwerp, Belgium) is the sponsor of the study. The funders had no role in the
599 design of the study, in the collection, analyses, or interpretation of data, in the writing of the
600 manuscript, or in the decision to publish the results.

601 **10 References**

- 602 1. Ngowi HA, Winkler AS, Braae UC, Mdegela RH, Mkupasi EM, Kabululu ML, et al.
603 *Taenia solium* taeniosis and cysticercosis literature in Tanzania provides research
604 evidence justification for control: A systematic scoping review. PLOS ONE. 2019;14:
605 e0217420. doi:10.1371/journal.pone.0217420
- 606 2. Zulu G, Stelzle D, Mwape KE, Welte TM, Strømme H, Mubanga C, et al. The
607 epidemiology of human *Taenia solium* infections: A systematic review of the
608 distribution in Eastern and Southern Africa. PLoS Negl Trop Dis. 2023;17: e0011042.
609 doi:10.1371/journal.pntd.0011042
- 610 3. Trevisan C, Devleesschauwer B, Schmidt V, Winkler AS, Harrison W, Johansen MV.
611 The societal cost of *Taenia solium* cysticercosis in Tanzania. Acta Trop. 2017;165: 141–
612 154. doi:10.1016/j.actatropica.2015.12.021

- 613 4. Gómez-Morales MA, Gárate T, Blocher J, Devleeschauwer B, Smit GSA, Schmidt V,
614 et al. Present status of laboratory diagnosis of human taeniosis/cysticercosis in Europe.
615 *Eur J Clin Microbiol Infect Dis.* 2017;36: 2029–2040. doi:10.1007/s10096-017-3029-1
- 616 5. Rodriguez S, Wilkins P, Dorny P. Immunological and molecular diagnosis of
617 cysticercosis. *Pathog Glob Health.* 2012;106: 286–298.
618 doi:10.1179/2047773212Y.0000000048
- 619 6. Mwape KE, Gabriël S. The Parasitological, Immunological, and Molecular Diagnosis of
620 Human Taeniasis with Special Emphasis on *Taenia solium* Taeniasis. *Curr Trop Med*
621 *Rep.* 2014;1: 173–180. doi:10.1007/s40475-014-0028-5
- 622 7. Yamasaki H, Allan JC, Sato MO, Nakao M, Sako Y, Nakaya K, et al. DNA differential
623 diagnosis of taeniasis and cysticercosis by multiplex PCR. *J Clin Microbiol.* 2004;42:
624 548–553. doi:10.1128/JCM.42.2.548-553.2004
- 625 8. Donadeu M, Fahrion AS, Olliaro PL, Abela-Ridder B. Target product profiles for the
626 diagnosis of *Taenia solium* taeniasis, neurocysticercosis and porcine cysticercosis. *PLoS*
627 *Negl Trop Dis.* 2017;11: e0005875. doi:10.1371/journal.pntd.0005875
- 628 9. Mubanga C, Mwape KE, Phiri IK, Trevisan C, Zulu G, Chabala C, et al. Progress on the
629 development of rapid diagnostic tests for foodborne neglected zoonotic helminthiasis: A
630 systematic review. *Acta Trop.* 2019;194: 135–147.
631 doi:10.1016/j.actatropica.2019.03.030
- 632 10. Van Damme I, Trevisan C, Mwape KE, Schmidt V, Magnussen P, Zulu G, et al. Trial
633 Design for a Diagnostic Accuracy Study of a Point-of-Care Test for the Detection of
634 *Taenia solium* Taeniasis and (Neuro)Cysticercosis in Community Settings of Highly
635 Endemic, Resource-Poor Areas in Zambia: Challenges and Rationale. *Diagnostics.*
636 2021;11: 1138. doi:10.3390/diagnostics11071138
- 637 11. Trevisan C, Van Damme I, Ngowi B, Schmidt V, Stelzle D, Møller KS, et al. Trial
638 Design of a Prospective Multicenter Diagnostic Accuracy Study of a Point-of-Care Test
639 for the Detection of *Taenia solium* Taeniasis and Neurocysticercosis in Hospital-Based
640 Settings in Tanzania. *Diagnostics.* 2021;11: 1528. doi:10.3390/diagnostics11091528
- 641 12. Mubanga C, Trevisan C, Van Damme I, Schmidt V, Phiri IK, Zulu G, et al. Challenges
642 Encountered When Evaluating an Antibody-Detecting Point-of-Care Test for Taeniasis
643 in an Endemic Community in Zambia: A Prospective Diagnostic Accuracy Study.
644 *Diagnostics.* 2021;11: 2039. doi:10.3390/diagnostics11112039
- 645 13. Mubanga C, Van Damme I, Trevisan C, Schmidt V, Phiri IK, Zulu G, et al. Evaluation
646 of an Antibody Detecting Point of Care Test for Diagnosis of *Taenia solium*
647 Cysticercosis in a Zambian Rural Community: A Prospective Diagnostic Accuracy
648 Study. *Diagnostics.* 2021;11: 2121. doi:10.3390/diagnostics11112121
- 649 14. Stelzle D, Makasi CE, Schmidt V, Van Damme I, Trevisan C, Ruether C, et al.
650 Evaluation of a point-of-care test for the diagnosis of *Taenia solium* neurocysticercosis
651 in rural southern Tanzania: a diagnostic accuracy study. *Lancet Infect Dis.* 2024;24: 98–
652 106. doi:10.1016/S1473-3099(23)00378-X

- 653 15. Zulu G, Stelzle D, Mwape KE, Van Damme I, Trevisan C, Mubanga C, et al. The
654 Performance of a Point-of-Care Test for the Diagnosis of Neurocysticercosis in a
655 Resource-Poor Community Setting in Zambia – a Diagnostic Accuracy Study.
656 Rochester, NY; 2024. doi:10.2139/ssrn.4746924
- 657 16. Stelzle D, Makasi C, Schmidt V, Trevisan C, Van Damme I, Welte TM, et al.
658 Epidemiological, clinical and radiological characteristics of people with
659 neurocysticercosis in Tanzania-A cross-sectional study. *PLoS Negl Trop Dis.* 2022;16:
660 e0010911. doi:10.1371/journal.pntd.0010911
- 661 17. Noh J, Rodriguez S, Lee Y-M, Handali S, Gonzalez AE, Gilman RH, et al.
662 Recombinant Protein- and Synthetic Peptide-Based Immunoblot Test for Diagnosis of
663 Neurocysticercosis. *J Clin Microbiol.* 2014;52: 1429–1434. doi:10.1128/JCM.03260-13
- 664 18. Levine MZ, Calderón S JC, Wilkins PP, Lane WS, Asara JM, Hancock K, et al.
665 Characterization, cloning and expression of two diagnostic antigens for *Taenia solium*
666 tapeworm infection. *J Parasitol.* 2004;90: 631–638. doi:10.1645/GE-189R
- 667 19. Mubanga C, Mwape KE, Phiri IK, Trevisan C, Kabululu M, Zulu G, et al. Operational
668 characteristics of an antibody detecting point of care test for *Taenia solium* infections in
669 a community and hospital setting. *BMC Infect Dis.* 2021;21: 607. doi:10.1186/s12879-
670 021-06320-3
- 671 20. Allan JC, Avila G, Noval JG, Flisser A, Craig PS. Immunodiagnosis of taeniasis by
672 coproantigen detection. *Parasitology.* 1990;101: 473–477.
673 doi:10.1017/S0031182000060686
- 674 21. Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, Bossche PV den, et al. *Taenia solium*
675 Infections in a Rural Area of Eastern Zambia-A Community Based Study. *PLoS Negl*
676 *Trop Dis.* 2012;6: e1594. doi:10.1371/journal.pntd.0001594
- 677 22. Levine MZ, Lewis MM, Rodriguez S, Jimenez JA, Khan A, Lin S, et al. Development
678 of an enzyme-linked immunoelectrotransfer blot (EITB) assay using two Baculovirus
679 expressed recombinant antigens for diagnosis of *Taenia solium* taeniasis. *J Parasitol.*
680 2007;93: 409–417. doi:10.1645/GE-938R.1
- 681 23. Dorny P, Phiri IK, Vercruyssen J, Gabriel S, Willingham AL, Brandt J, et al. A Bayesian
682 approach for estimating values for prevalence and diagnostic test characteristics of
683 porcine cysticercosis. *Int J Parasitol.* 2004;34: 569–576.
684 doi:10.1016/j.ijpara.2003.11.014
- 685 24. Berkvens D, Speybroeck N, Praet N, Adel A, Lesaffre E. Estimating disease prevalence
686 in a Bayesian framework using probabilistic constraints. *Epidemiology.* 2006;17: 145–
687 153. doi:10.1097/01.ede.0000198422.64801.8d
- 688 25. Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, et al.
689 STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use
690 Bayesian Latent Class Models. *Prev Vet Med.* 2017;138: 37–47.
691 doi:10.1016/j.prevetmed.2017.01.006

- 692 26. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the
693 paradoxes. *J Clin Epidemiol.* 1990;43: 551–558. doi:10.1016/0895-4356(90)90159-M
- 694 27. R Core Team. R: A language and environment for statistical computing. Vienna,
695 Austria: R foundation for statistical computing; 2023. Available: [https://www.R-](https://www.R-project.org/)
696 [project.org/](https://www.R-project.org/)
- 697 28. Praet N, Verweij JJ, Mwape KE, Phiri IK, Muma JB, Zulu G, et al. Bayesian modelling
698 to estimate the test characteristics of coprology, coproantigen ELISA and a novel real-
699 time PCR for the diagnosis of taeniasis. *Trop Med Int Health.* 2013;18: 608–614.
700 doi:10.1111/tmi.12089
- 701 29. Zea-Vera A, Cordova EG, Rodriguez S, Gonzales I, Pretell EJ, Castillo Y, et al. Parasite
702 Antigen in Serum Predicts the Presence of Viable Brain Parasites in Patients With
703 Apparently Calcified Cysticercosis Only. *Clin Infect Dis.* 2013;57: e154–e159.
704 doi:10.1093/cid/cit422
- 705 30. Corda M, Sciarba J, Blaha J, Mahanty S, Paredes A, Garcia HH, et al. A recombinant
706 monoclonal-based Taenia antigen assay that reflects disease activity in extra-
707 parenchymal neurocysticercosis. *PLoS Negl Trop Dis.* 2022;16: e0010442.
708 doi:10.1371/journal.pntd.0010442
- 709 31. Dermauw V, Carabin H, Cissé A, Millogo A, Tarnagda Z, Ganaba R, et al. Evaluating
710 the Recombinant T24H Enzyme-Linked Immunoelctrotransfer Blot Assay for the
711 Diagnosis of Neurocysticercosis in a Panel of Samples from a Large Community-Based
712 Randomized Control Trial in 60 Villages in Burkina Faso. *Am J Trop Med Hyg.*
713 2017;98: 565–569. doi:10.4269/ajtmh.17-0541
- 714 32. Morillo M, Noguera C, Gallego L, Fernández Z, Mata M, Khattar S, et al.
715 Characterization and evaluation of three new recombinant antigens of Taenia solium for
716 the immunodiagnosis of cysticercosis. *Mol Biochem Parasitol.* 2020;240: 111321.
717 doi:10.1016/j.molbiopara.2020.111321
- 718 33. Castillo Y, Toribio LM, Guzman C, Arroyo G, Espinoza C, Saavedra H, et al.
719 Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with
720 Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-
721 Linked Immunosorbent Assays. *Pathogens.* 2023;12: 566.
722 doi:10.3390/pathogens12040566
- 723 34. Gabriël S, Blocher J, Dorny P, Abatih EN, Schmutzhard E, Ombay M, et al. Added
724 value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings.
725 *PLoS Negl Trop Dis.* 2012;6: e1851. doi:10.1371/journal.pntd.0001851
- 726 35. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case–Control and
727 Two-Gate Designs in Diagnostic Accuracy Studies. *Clin Chem.* 2005;51: 1335–1341.
728 doi:10.1373/clinchem.2005.048595
- 729 36. Handali S, Klarman M, Gaspard AN, Dong XF, LaBorde R, Noh J, et al. Development
730 and Evaluation of a Magnetic Immunochromatographic Test To Detect Taenia solium,

731 Which Causes Taeniasis and Neurocysticercosis in Humans. *Clin Vaccine Immunol*
732 *CVI*. 2010;17: 631–637. doi:10.1128/CVI.00511-09

733 37. Gass K. Time for a diagnostic sea-change: Rethinking neglected tropical disease
734 diagnostics to achieve elimination. *PLoS Negl Trop Dis*. 2020;14: e0008933.
735 doi:10.1371/journal.pntd.0008933

736

737

738 **Supporting information Captions**

739 **S1 Appendix. Patient recruitment.** Table 1A Recruitment of cohort 1 participants from the
740 outpatient department and mental health clinic. Table 1B. Symptoms of participants in cohort
741 1 during recruitment. The results are from screening questionnaires administered by local
742 nurses.

743 **S2 Appendix. Output of Bayesian analyses.**

Excluded (n=141)

- Reason for recruitment unclear (n=3)
- Incorrect headache criteria used (n=138)

No reference test results

- Not selected (n = 462)
- No serum sample (n=4)
- No stool sample (n=4)

No reference test results

- No serum sample (n=9)
- No stool sample (n=9)

No reference test results
- Not selected (n = 1497)
- No serum sample (n=29)
- No stool sample (n=26)

No reference test results
- No serum sample (n=11)
- No stool sample (n=11)

No reference test results
- No serum sample (n=2)
- No stool sample (n=2)

Excluded (n = 1)
- Symptoms not clear (n = 1)

No reference test results
- Not selected (n = 594)
- No serum sample (n=10)
- No stool sample (n=11)

No reference test results
- No serum sample (n=3)
- No stool sample (n=1)